The use of UCOE vectors in combination with a preadapted serum free, suspension cell line allows for rapid production of large quantities of protein
- PMID: 19003085
- PMCID: PMC3449923
- DOI: 10.1023/A:1021141712344
The use of UCOE vectors in combination with a preadapted serum free, suspension cell line allows for rapid production of large quantities of protein
Abstract
UCOE vectors contain non-tissue specific chromatin-opening-elements that permit rapid expression of a protein in anintegration independent manner. Efficient expression can bederived from a single copy of an integrated gene site resulting ina higher percentage of cells expressing the marker gene in theselected pool in comparison to standard non-UCOE containingvectors. This, in combination with the utilization of a serum-free, suspension adapted parent cell line allows for rapidproduction of large quantities of protein in a short period oftime. Utilizing this system more than 300 mg of a recombinantantibody has been produced in less than 1 month from transfectionpools in shake flask. Selected subclones have been scaled intosmall bioreactors in less than 2 months, producing significantquantities of monoclonal antibody using a protocol generic for theparent cell line. The increased efficiency obtained with the UCOEvector reduces the number of transfectants which need to bescreened in order to obtain high productivity subclones.Transfection of a standard host cell line, preadapted to grow in alarge-scale setting, allows for rapid cell line developmentdecreasing the transition time from research into development andmanufacturing. Alternatively, the traditional approach of using aparent cell line which requires serum-free and suspensionadaptation after transfection further increases the need forscreening a large number of subclones, because many of thesubclones will not be able to grow under conditions that allowlarge-scale protein production. The use of a preadapted cell linecan reduce the time required to develop a cell line from months toweeks.
References
-
- Borrebeack CM, Ohlin M. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol Today. 1993;14:477–479. - PubMed
-
- Cho SK, Cummings RD. A soluble form of α1,3-galactosyltransferase functions within cells to glycosylate proteins. J Biol Chem. 1997;272:13622–13628. - PubMed
-
- Crombie R & Antoniou M (2000) A Polynucleotide Comprising a Ubiquitous Chromatin Opening Element (UCOE). Patent Number WO0005393, 2000-02-03.
-
- D'Anna JA, Valdez JG, Habbersett RC, Crissman HA. Association of G1/S-Phase and Late S-Phase Checkpoints with Regulation of Cyclin-Dependent Kinases in Chinese Hamster Ovary Cells. Rad Res. 1997;148:260–271. - PubMed
-
- D'Anna JA, Crissman HA, Valdez JG, Gurley LR, Tobey RA. Syncronization of mammalian cells in S-phase by sequential use of isoleucine-deprivation G1-or serum-withdrawl G0-arrest and aphidicolin block. Meth Cell Sci. 1996;18:115–125.
LinkOut - more resources
Full Text Sources
Other Literature Sources
